B49AECDA-9EAE-45DD-B427-AF5D829E0F1C

Qlucore Insights Models (RuO)

We work with scientific experts to develop disease specific classifier models for subtype determination. The machine learning (AI) based classifiers are combined with user-friendly visualizations and also supports gene fusion detection and analysis. Currently four models are available and more are being developed.

  • Acute lymphoblastic leukemia (BCP-ALL)
  • Lung cancer with detection of metastasis origin 
  • AML
  • Urothelial carcinoma - Bladder cancer 

The Qlucore Insights Models are for research use only (RuO). Development of models for Qlucore Diagnostics is ongoing with a target for apporval according to IVDR. 

BCP-ALL (RuO)

Gene expression based subtype classification in combination with comprehensive gene fusion analysis. With the inclusion of the DUX4-rearranged and  ETV6::RUNX1-like subtypes up to 7% more of the children are covered compared to standard methods. Supported subtypes:

1. High hyperdiploidy
2. ETV6::RUNX1 + ETV6::RUNX1-like
3. KMT2A(MLL)-rearranged (MLL)
4. TCF3::PBX1
5. BCR::ABL1 + BCR::ABL1-like
6. DUX4-rearranged

More information regarding BCP-ALL

Blood

Lung cancer with detection of metastasis origin (RuO)

Detection of origin for metastatic tumors for the following types; Breast invasive carcinoma (BRCA), Colon adenocarcinoma (COAD), rectum adenocarcinoma (READ), kidney renal clear cell carcinoma (KIRC), bladder urothelial carcinoma (BLCA) and head and neck squamous cell carcinoma (HNSC).

Unbiased classification of LUAD and LUSC.

Gene fusion detection and analysis using up to three different gene fusion callers.

Sample: FFPE

Lung cancer

AML (RuO)

This model is under develoment and further improvements are expected. The first generation detects the following subtypes:

  • CBFB::MYH11
  • NPM1
  • PML:RARA
  • RUNX1::RUNX1T1

Sample type: Fresh frozen

DNA

Urothelial carcinoma - Bladder cancer (RuO)

Gene expression based subtyping into five subtypes:

  • Basal/SCC-like 
  • Genomically Unstable (GU) 
  • Mesenchymal-like (Mes-like) 
  • Small-Cell/Neuroendocrine-like (Sc/NE-like) 
  • Urothelial-like 

Three benefits based on correct molecular subtype classification:

For grade T1 tumours (NMIBC): Identification of  Basal/Squamous-like subtype (Ba/Sq-like) and Genomically Unstable subtype (GU). Ba/Sq and GU should be considered for radical surgery due to increased risk of progression. Improves on current risk score algorithm.

For grade T2-T4 tumours (MIBC): De-escalate the use of  neoadjuvant chemotherapy (NAC) by refraining from NAC in patients with Basal/Squamous-like subtype (Ba/Sq-like) (Ba/Sq-like tumours respond less frequently).

Metastatic disease: Prediction of response on PD1 & PDL1 inhibitors. More frequently response in the GU subtype.

Bladder cancer